Key facts
- It has raised $19.8M; the latest was Seed Round ($19.8M) in Mar 2026.
- Notable investors include Kurma Partners, Angelini Ventures, ROM Utrecht Region, Argobio Studio, Biovance Capital Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Laigo Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Laigo Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Laigo Bio
Developer of a biotechnology platform designed to develop dual-targeted therapies through protein degradation. The company's platform focuses on developing a biological approach to treat tumors and neurological diseases by targeting chimeric molecules via surface removal, enabling medical professionals to achieve sustained degradation of target receptors.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2021
- Employees
- 3
- Website
- laigobio.com/
- Ownership
- Privately Held (backing)
Laigo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laigo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laigo Bio in its N-PORT filings yet. We sweep new filings monthly.